scholarly journals Steroid pulse therapy in severe systemic lupus erythematosus.

1990 ◽  
Vol 13 (1) ◽  
pp. 9-17
Author(s):  
Shingo Iijima ◽  
Yoshifusa Kishigami ◽  
Susumu Nishinarita ◽  
Shigemasa Sawada ◽  
Takashi Horie
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Pulse Therapy ◽  
Steroid Pulse Therapy ◽  
Systemic Lupus ◽  
Steroid Pulse ◽  
Severe Systemic Lupus Erythematosus

Central nervous system manifestations after steroid pulse therapy in systemic lupus erythematosus

2002 ◽  
Vol 161 (9) ◽  
pp. 503-504 ◽  
Author(s):  
Yuichi Tabata ◽  
Ichiro Kobayashi ◽  
Nobuaki Kawamura ◽  
Motohiko Okano ◽  
Kunihiko Kobayashi
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Central Nervous System ◽  
Nervous System ◽  
Lupus Erythematosus ◽  
Pulse Therapy ◽  
Steroid Pulse Therapy ◽  
Systemic Lupus ◽  
Steroid Pulse

Two cases of anaphylactic shock by methylprednisolone in neuromyelitis optica

2018 ◽  
Vol 24 (11) ◽  
pp. 1514-1516 ◽  
Author(s):  
Keita Takahashi ◽  
Tetsuya Asano ◽  
Yuichi Higashiyama ◽  
Shigeru Koyano ◽  
Hiroshi Doi ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Autoimmune Disease ◽  
Neuromyelitis Optica ◽  
Lupus Erythematosus ◽  
Anaphylactic Shock ◽  
Alternative Therapy ◽  
Pulse Therapy ◽  
Steroid Pulse Therapy ◽  
Systemic Lupus ◽  
Steroid Pulse

Steroid pulse therapy with methylprednisolone (mPSL) succinate ester is the most common treatment for neuromyelitis optica (NMO); no cases of anaphylaxis have been reported to date. Here, we report two cases of anaphylactic shock induced by mPSL pulse therapy in patients with NMO and concurrent systemic lupus erythematosus. Both patients had received several courses of mPSL pulse therapy without any problems previously. Repeated mPSL pulse therapy and comorbid humoral autoimmune disease might increase the risk of anaphylaxis. Corticosteroids without succinate esters should be considered as an alternative therapy to prevent anaphylaxis.

The risk of hospitalized infection in patients with systemic lupus erythematosus treated with hydroxychloroquine

Lupus ◽  
2020 ◽  
Vol 29 (13) ◽  
pp. 1712-1718 ◽  
Author(s):  
Ryoko Sakai ◽  
Suguru Honda ◽  
Eiichi Tanaka ◽  
Masako Majima ◽  
Naoko Konda ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Propensity Score ◽  
Lupus Erythematosus ◽  
Claims Data ◽  
Pulse Therapy ◽  
Immunosuppressive Drugs ◽  
Steroid Pulse Therapy ◽  
Diagnostic Code ◽  
Systemic Lupus ◽  
Steroid Pulse

Objective To compare the risk of hospitalized infection (HI) between users and non-users of hydroxychloroquine (HCQ) in systemic lupus erythematosus (SLE). Methods Using claims data, patients were defined as SLE cases by the following criteria: 1) they had at least one SLE diagnostic code; 2) they had a prescription for specific drugs, including corticosteroids, steroid pulse therapy, and immunosuppressive drugs; and 3) they were at least 16 years old between September 2015 and July 2017 (n = 17,483). The SLE cases with at least one prescription for HCQ were defined as the HCQ group (n = 1,431), while the others were defined as the non-HCQ group. Among the SLE cases, propensity score-matched cases were observed for 1 year (n = 1,095 in each group). Results The median age and proportion of female patients in both groups were about 42 years and 88%, respectively. The proportions of cases with HIs were similar (HCQ group, 4.5%; non-HCQ group, 5.6%; p = 0.240, McNemar test). The hazard ratio of the HCQ group for HIs after adjusting for patients’ characteristics was not significant at 0.9 (0.6–1.3). Conclusion The use of HCQ was not associated with a risk of HIs in patients with SLE.

scholarly journals A case of systemic lupus erythematosus with pure red cell aplasia responded to steroid pulse therapy.

1991 ◽  
Vol 14 (6) ◽  
pp. 639-645
Author(s):  
Tatsuya Atsumi ◽  
Akira Sagawa ◽  
Kazuaki Katsumata ◽  
Yoshiharu Amasaki ◽  
Tohru Nakabayashi ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Pure Red Cell Aplasia ◽  
Pulse Therapy ◽  
Steroid Pulse Therapy ◽  
Red Cell ◽  
Systemic Lupus ◽  
Steroid Pulse ◽  
Red Cell Aplasia

Reactive Hemophagocytic Syndrome in Adult Korean Patients with Systemic Lupus Erythematosus: A Case-Control Study and Literature Review

2011 ◽  
Vol 39 (1) ◽  
pp. 86-93 ◽  
Author(s):  
JI-MIN KIM ◽  
SEUNG-KI KWOK ◽  
JI HYEON JU ◽  
HO-YOUN KIM ◽  
SUNG-HWAN PARK
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Hemophagocytic Syndrome ◽  
Pulse Therapy ◽  
Albumin Level ◽  
Systemic Lupus ◽  
Acute Phase Reactants ◽  
Sledai Score ◽  
Steroid Pulse ◽  
Korean Patients

Objective.To determine the characteristics of hemophagocytic syndrome (HPS) in adult Korean patients with systemic lupus erythematosus (SLE).Methods.We reviewed the medical records of 1033 adult patients with SLE for a recent 14-year period and identified 15 patients who had developed HPS. Forty-two age- and sex-matched patients with SLE admitted for other manifestations were included as disease controls. Features of HPS in these patients were analyzed.Results.Reactive HPS occurred from some distinct causes during the course of SLE. HPS was associated with SLE in 11 patients (4 at onset of SLE and 7 at SLE flare), infection in 3 patients (2 bacterial infection; 1 viral infection), and drug use (azathioprine) in 1 patient. Common clinical features included fever (93.3%), hepatomegaly (60.0%), and splenomegaly (60.0%). Steroid pulse therapy (46.7%), immunosuppressants (46.7%), and intravenous immunoglobulin (46.7%) were frequently used for treatment of HPS. One patient (6.7%) died. Compared with SLE patients without HPS, those with HPS showed a higher SLEDAI score (p = 0.003) and lower levels of plasma leukocytes (p < 0.001), hemoglobin (p = 0.013), and platelets (p < 0.001) as well as a higher serum C-reactive protein level (p = 0.039) and a lower serum albumin level (p = 0.004).Conclusion.HPS was observed in 1.5% of adult Korean patients with SLE. The occurrence of HPS was most frequently associated with the SLE disease activity. Profound pancytopenia, a high SLEDAI score, and notable changes in the level of acute-phase reactants can be the characteristics of SLE patients with HPS.

Sign in / Sign up

Export Citation Format

Share Document